Our Commitment
At Atrium Therapeutics, individuals and families living with rare, genetically driven cardiomyopathies are the reason we exist. We are working to transform care for these serious, progressive conditions that today have no approved therapies designed to address the root cause. By pioneering a new way to deliver RNA-based medicines to the heart, we are pursuing the genetic drivers of disease that have long been out of reach.
As we pave a new path for precision cardiology, we are committed to listening to and learning from people living with rare, genetically driven cardiomyopathies like PRKAG2 syndrome and PLN cardiomyopathy. Want to connect with our team? Send us an email at: patients@atrium-tx.com
Clinical Trials
The Corventis clinical trial is currently evaluating ATR-1072, an investigational therapy being studied for the treatment of PRKAG2 Syndrome.